HBV and liver cancer.
The association of hepatitis B virus (HBV) infection and liver cancer is well documented in epidemiological study. Patients with chronic hepatitis B have increased risk of hepatocelluar carcinoma (HCC), in particular those with active liver disease and cirrhosis. The incidence of HCC increases with age and is more common among male patients. The introduction of universal HBV vaccination program for the newborn in endemic regions has started to show beneficial impact. Taiwan introduced this program two decades ago and the incidence of liver cancer among infants and young children have declined significantly. The carcinogenic events leading to HCC are under intense research. A number of hypotheses have been proposed. HBV is not directly hepatotoxic but its interaction with the host immune system creates opportunity for HBV DNA integration into the host genome. One of the main foci of research is the HBX-encoded X protein. Its integration and protein expression impose alteration in cell proliferation cycle and apoptosis process. Many other factors may be involved including viral-induced alterations in p53 and telemerase, HBV genotypes, co-infection with HCV or delta agents, patient's lifestyle such as smoking, alcohol excesses, and genetic factors of the host patient. The processes of necroinflammation, cell proliferation and fibrosis facilitate the initial carcinogenic development. HCC surveillance with tumor markers such as alpha-foetal protein, decarboxylated prothrombin, in conjunction with imaging techniques has identified early small HCC that is amenable to curative therapy. Viral load has been correlated with increase risk of HCC. The available anti-viral agents have demonstrated clinical benefit among those with maintained and sustained response. Interferon and lamivudine therapy have demonstrated reduction of HCC among responders. However, they only constitute a minority proportion of treated patients. The mainstay of prevention should lie in prevention of HBV infection and early effective therapy of chronic hepatitis B infection.
Leung
Nancy
N
Alice Ho Miu Ling Nethersole Hospital and The Chinese University of Hong Kong, Hong Kong, SAR, China.
D000367:Age Factors; D015897:Comorbidity; D006509:Hepatitis B / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000276:immunology; D006723:Hong Kong / Q000453:epidemiology; D006801:Humans; D017589:Immunization Programs; D008103:Liver Cirrhosis; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000209:etiology; D012307:Risk Factors
D017325:Hepatitis B Vaccines